High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE−/− mice by Yee Kwan Chan et al.
RESEARCH ARTICLE Open Access
High fat diet induced atherosclerosis is
accompanied with low colonic bacterial
diversity and altered abundances that
correlates with plaque size, plasma A-FABP
and cholesterol: a pilot study of high fat
diet and its intervention with Lactobacillus
rhamnosus GG (LGG) or telmisartan in
ApoE−/− mice
Yee Kwan Chan1*, Manreetpal Singh Brar2*, Pirkka V. Kirjavainen3, Yan Chen4, Jiao Peng4, Daxu Li4,
Frederick Chi-Ching Leung2,5 and Hani El-Nezami1,6,7*
Abstract
Background: Atherosclerosis appears to have multifactorial causes – microbial component like lipopolysaccharides
(LPS) and other pathogen associated molecular patterns may be plausible factors. The gut microbiota is an ample
source of such stimulants, and its dependent metabolites and altered gut metagenome has been an established
link to atherosclerosis. In this exploratory pilot study, we aimed to elucidate whether microbial intervention with
probiotics L. rhamnosus GG (LGG) or pharmaceuticals telmisartan (TLM) could improve atherosclerosis in a gut
microbiota associated manner.
Methods: Atherosclerotic phenotype was established by 12 weeks feeding of high fat (HF) diet as opposed to normal
chow diet (ND) in apolipoprotein E knockout (ApoE−/−) mice. LGG or TLM supplementation to HF diet was studied.
Results: Both LGG and TLM significantly reduced atherosclerotic plaque size and improved various biomarkers including
endotoxin to different extents. Colonial microbiota analysis revealed that TLM restored HF diet induced increase in
Firmicutes/Bacteroidetes ratio and decrease in alpha diversity; and led to a more distinct microbial clustering closer to ND
in PCoA plot. Eubacteria, Anaeroplasma, Roseburia, Oscillospira and Dehalobacteria appeared to be protective against
atherosclerosis and showed significant negative correlation with atherosclerotic plaque size and plasma adipocyte – fatty
acid binding protein (A-FABP) and cholesterol.
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Conclusion: LGG and TLM improved atherosclerosis with TLM having a more distinct alteration in the colonic gut
microbiota. Altered bacteria genera and reduced alpha diversity had significant correlations to atherosclerotic plaque size,
plasma A-FABP and cholesterol. Future studies on such bacterial functional influence in lipid metabolism will be warranted.
Keywords: Atherosclerosis, Probiotics, LGG, Telmisartan, Gut microbitoa
Background
Atherosclerosis is the major cause of myocardial infarc-
tion and stroke, which accounts to the leading cause of
death worldwide [1, 2]. Atherosclerosis is a chronic
inflammatory disease of the arteries – inflammation is
present and mediated by different chemokines/cytokines
at all stages – from leukocytes recruitment by adhesion
molecules in plaque formation to collagen cap digestions
by metalloproteinases (MMPs) that contributes to the
plaque instability.
Recently, there is more evidence that associates the
gut microbiota to atherosclerosis. Endotoxin has become
a popular candidate as the initiator of obesity and insulin
resistance [3], not only can gut microbiota modulate
endotoxemia [4], endotoxemia can also be resulted from
a weakened gut barrier where endotoxin (LPS) and other
bacterial products can easily leak into the circulation
and trigger inflammatory response. Gastrointestinal (GI)
track has been suggested to be the major site for patho-
gen associated molecular patterns (PAMPs) absorption
and translocation [5]. Toll like receptors (TLRs) com-
pose a family of recognition receptors for PAMPs, play-
ing important roles in eliciting innate and adaptive
immune responses [6]. TLR2, TLR4 and TLR5 can
recognize and be activated by bacterial components
found in the gut microbiota – peptidoglycan, LPS, and
flagella respectively [7]. Inflammatory responses are
augmented upon the activation of TLRs by NFκB and
transcriptional activation of genes that encode pro-
inflammatory cytokines and chemokines. With obesity
and insulin resistance being major risk factors for ath-
erosclerosis and cardiovascular diseases [8], it is not
surprising to find endotoxin capable in accelerating and
acts as a potent mediator for atherosclerosis [9–11].
Furthermore, presence and correlations of bacterial
DNA in the atherosclerotic plaque to their abundance
found in the GI tract had provided further support to
potential causative links of the gut microbiota to athero-
sclerosis [12]. Investigations on modulating the gut
microbiota in an attempt to reduce cardiovascular risks
had increased significantly in the last decade – from
realizing the potential of probiotics in improving lipid
profile [13–16] and atherosclerotic plaque size [17, 18],
and to finding the gut metagenome having a different func-
tional capacity in symptomatic atherosclerotic patients [19],
to recently identifying the gut microbiota dependent
metabolites that significantly increase cardiovascular risks
[20], have all contributed in assuring the metabolic role of
gut microbes in atherosclerosis.
In this pilot study, we aimed to investigate whether
probiotics and pharmaceutical interventions could im-
prove atherosclerosis in a gut microbiota associated
manner in a well-established atherosclerotic animal
model, ApoE−/− mice [21–23]. L. rhamnosus GG (LGG),
one of the best clinically-documented probiotic strains
[24], was first isolated more than 20 years ago by Goldin
and Gorbach from a faecal sample from a healthy adult
and showed to have high resistance against gastric acid
and high persistence capacity in the human GI tract
[25]. As it has proven benefits in various diseases including
diarrhea [26, 27], colitis [28] and atopic disease [29, 30];
and its high adaptability in the GI tract, LGG is often
regarded as a model probiotic strain [31]. To better
compare the capability and the extent to how LGG
may improve atherosclerosis, a positive control was
introduced by the pharmaceutical intervention of
telmisartan (TLM). TLM is a dual angiotensin II
receptor blocker and partial perixosome proliferator-
activated receptor Ɣ (PPARƔ) agonist. Clinically,
TLM is used to treat hypertension, including patients
with atherosclerosis [32], and can improve endothelial
[33] and cardiovascular [34] functions. In vivo, it was
proven to relieve atherosclerosis in the ApoE−/− mice
[35–37], and had recently been documented to reduce
colonic inflammation in rats with inflammatory bowel
disease [38]. We examined the effects of LGG and
TLM supplementation in HF diet in terms of several
atherosclerosis parameters and colonic gut microbiota,
and identified some potentially important gut mi-
crobes in the pathogenesis of atherosclerosis.
Methods
Animals
Six-weeks-old female ApoE−/− mice were fed ad libitum
on a normal chow diet for 1 week before being contin-
ued at normal chow diet (ND) (D10001, Research Diet)
or powdered 21gm% high fat diet (D12079B, Research
Diet) without (HF) or with Lactobacillus rhamnosus GG
(LGG) (ATCC 53103) (Vailo) (HF + LGG) or telmisartan
(TLM) (Micardis®, Boehringer Ingelheim GmbH) at
5 mg/kg/day (HF + TLM) for 12 weeks. Ingredients of
the ND and HF diets can be found in Tables 1 and 2.
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For this pilot study, the number of mice used in ND, HF,
HF + LGG and HF + TLM groups were 5, 4, 3 and 5
respectively. The dose of LGG at 1×108 CFU/day was
converted from the recommended human dose using
the Body Surface Area normalization method [39].
Lyophilized LGG powder was mixed in the HF diet;
TLM was mixed into the drinking water – oral gavage
was avoided to prevent stress induced immunomodula-
tion. Fecal recovery of LGG has been tested to be at
approximately 1×106CFU/g by fecal dilution and plating
on LB plates (data not shown). Food and water con-
sumption was monitored twice a week to adjust LGG or
TLM dosages. All animals were kept in the Animal
Laboratory of the Department of Surgery at 23–24 °C
and relative humidity at 60–70 % on 12/12 h day/night
cycle. All study protocols were approved by the Commit-
tee on the Use of Live Animals in Teaching and
Research (CULATR) of the University of Hong Kong and
the Department of Health of the HKSAR Government.
Quantification of plasma biomarkers
Mice were fasted overnight before sacrifice. Blood was
collected in tubes coated with EDTA followed by centri-
fugation at 5,000 rpm for 10 min. Plasma was collected,
aliquoted and stored at −80 °C until use. The plasma
concentration of the following biomarkers were quanti-
fied using Milliplex™ MAP kits and Luminex 200
Analyzer (Merck Millipore) following the manufacturer’s
protocol: ghrelin with Milliplex®MAP Mouse Gut hor-
mone Panel; sE-selectin, MMP-9, sICAM-1 and
sVCAM-1 with Milliplex®MAP Mouse Cardiovascular
Disease Panel I kit; IL-33 with Milliplex®MAP Mouse
Cytokine/Chemokine Panel III Immunoassay respect-
ively; with data acquisition and basic data analysis using
xPONENT 3.1 and advanced data analysis using Milli-
plex Analyst 3.5. Plasma A-FABP and cholesterol was
quantified using Mouse Adipocyte FABP ELISA Kit (Bio-
Vendor Research and Diagnostic Products Brno) and
Cholesterol Assay Kit (Cayman Chemical Company) re-
spectively following manufacturer’s protocol. Plasma
endotoxin was quantified with Lonza Limulus amebo-
cyte lysate (LAL) QCL-1000 (Lonza) following manufac-
turer’s protocol with heat inactivation at 75 °C for
10 min and addition of β-glucan blocker (Lonza) (1:1) to
inhibit false positive readings generated by contamin-
ation from β-1,3-glucans.
Assessment of atherosclerotic plaque size
Aortic sinus
Hearts were harvested, fixed in 4 % PFA overnight, em-
bedded in Tissue-Tek® OCT compound (Sakura Finetek)
and stored at −20 °C before cryosectioned serially at
10 μm intervals from the aortic sinus and mounted on
slides (Superfrost plus). Oil Red O Solution was freshly
prepared as previously described [40] and used within
2 h of preparation. Slides were stained with Leica
ST5020 Multistainer (Leica Microsystems Inc) for better
consistency. Briefly, slides were immersed in tap water
for 2 min, 60 % isopropanol for 30s, Oil Red O Solution
for 18 min, 60 % isopropanol for 30s, tap water for
2 min, hematoxylin for 2 min, tap water for 3 min, 2 %
acetic acid for 3 s, tap water for 20 s, Bluing solution for
1 min and tap water for 1 min before air drying. Images
for viewed and captured with Nikon 80i Microscope and
lesion quantified using SPOT™ Software 4.7.
Aortic tree
Fat tissue and adventitious blood vessels were removed
from the inferior vena cava carefully with micro-scissors
and micro-dissection forceps under dissecting micro-
scope. The inferior vena cava was harvested and stored
in PBS at 4 °C until use. Sudan IV solution was prepared
by preparing 0.5 % Sudan IV in 35 % ethanol and 50 %
acetone followed by filtration. The artery was placed flat
Table 1 Protein, carbohydrate and fat content of ND and HF diet
used in this pilot study
ND HF
gm % kcal % gm % kcal %
Protein 20.3 20.8 20 17
Carbohydrates 66 67.7 50 43
Fat 5 11.5 21 41
Total 100 100
kcal/gm 3.9 4.7
Table 2 Ingredients of ND and HF diet used in this pilot study
ND HF
Ingredient gm kcal gm kcal
Caesin 30 Mesh 200 800 0 0
Caesin, 80 Mesh 0 0 195 780
DL-Methionine 3 12 3 12
Corn starch 150 600 50 200
Maltodextrin 10 0 0 100 400
Sucrose 500 2000 341 1364
Cellulose, BW200 50 0 50 0
Milk fat, anhydrous 0 0 200 1800
Corn oil 50 450 10 90
Mineral Mix S10001 35 0 35 0
Calcium carbonate 0 0 4 0
Vitamin Mix V10001 10 40 10 40
Choline Bitartrate 2 0 2 0
Cholesterol, USP 0 0 1.5 0
Ethoxyquin 0 0 0.04 0
Total 1000 3902 1001.54 4686
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on a Petri dish, first rinsed with 70 % ethanol,
stained with Sudan IV solution for 5 min and de-
stained in 80 % ethanol for 6 min before being
viewed under a Zoom Stereo Microscope (Olympus
SZX7®) and images captured with an Olympus DP71
Microscope Digital Camera. Areas stained red were
considered atherosclerotic lesions and were quanti-
fied using Image J software.
Colonial gut microbiota evaluation
DNA was extracted from colon using QIAamp® DNA
Stool Mini Kit (Qiagen) followed by amplification of the
V4-6 region of the 16S rRNA gene at position 563 to
1064 with a product size of 573 bp with Expand High
FidelityPLUS PCR System (Roche). Each 25 μl of PCR
mixture contained: 1× Expand High FidelityPLUS Reac-
tion Buffer with 1.5 mM MgCl2; 200 μM PCR Grade
Nucleotide Mix; 0.4 μM of the forward and reverse
primers, 1.25U of Expand HiFiPLUS Enzyme Blend and
5–500 ng of template genomic DNA isolated from the
mouse colon. The PCR protocol involved denaturation
at 95 °C for 2 min; 35 cycles of denaturation at 95 °C for
20 s, annealing temperature at 53 °C for 30 s and exten-
sion at 72 °C for 40 s; and a final extension at 72 °C for
10 min. Target PCR products were verified on 1 % agar-
ose gel with TAE buffer. A band of 573 bp was gel-
purified with QIAquick® Gel Extraction Kit (Qiagen) and
the final concentration of the amplicon was quantified
using Quant-iT™PicoGreen® dsDNA assay (Invitrogen).
Library preparation, emPCR amplification and picotitre
plate pyrosequencing using titanium chemistry was car-
ried out in accordance with Roche/454 Life Sciences
protocols on the 454 GS Junior (454 Life Sciences-a
Roche Company). A total of 397,743 sequence reads
were generated, with an average of 23,397 reads per
sample. All sequence reads derived from the 454 GS
Junior pyrosequencer were analyzed using Quantita-
tive Insights Into Microbial Ecology (QIIME) [41].
Prior to sequence analysis, all raw reads were
denoised to reduce sequencing errors and avoid artifi-
cial inflation of OTU diversity and processed for
quality trimming. Quality trimming parameters in-
cluded removal of forward and reverse primer se-
quences, retaining a minimum sequence length of
150 bp; maximum sequence length of 573 bp; mini-
mum quality score of 25 in a 50 bp sliding window.
Quality trimmed reads were demultiplexed based on
pre-designed barcodes followed by determination of
operational taxonomic units (OTUs) by clustering
sequences with a similarity threshold of 97 % using
uclust. Representative sequences were picked and
aligned using MUSCLE (Multiple Sequence by Log-
Expectation) against the Greengenes Core Set data
followed by taxonomy assignment to each sequence
using the Blast algorithm after screening and elimin-
ating chimeric reads. Subsequent analysis included
relative and absolute abundance of bacteria, alpha
and beta diversity and principal coordinates (PCoA)
plots based on unweighted UniFrac using inherent
scripts within the QIIME package. All 454 sequence
data associated with this study has been deposited in
the NCBI SRA repository under the study accession
no. SRP026050.
Statistical analysis
Data are expressed as mean ± SEM. Data normality was
analyzed using Shapiro-Wilk test [42]. Kruskal-Wallis
Test with Dunns post hoc tests were used to analyze
nonparametric data; One Way ANOVA with Bonferroni
post hoc tests were used to analyze parametric data.
Statistical tests were done using GraphPad Prism 5.
Correlation studies were done using R [43]. P < 0.05 was
considered statistically significant.
Results
LGG and TLM significantly reduced high fat diet induced
atherosclerosis plaque size at aortic sinus and aortic tree
The lesion at the aortic root (Fig. 1a LHS) and aortic
tree (Fig. 1b and magnified at Fig. 1a RHS) was
stained red with Oil Red O and Sudan IV respect-
ively. 12 weeks of HF diet significantly increased
lesion area in ApoE−/− mice at the aortic sinus by 8
fold, from a mean for ND at 0.06 mm2 to HF at
0.59 mm2. LGG and TLM supplementation reduced
the lesion size by 37 % (0.37 mm2) and 80 %
(0.12 mm2) respectively (Fig. 1c). Comparable results
were seen at the aortic tree – the lesion area in HF
was 2.21 fold higher than ND (0.12 cm2 vs 0.04 cm2,
respectively), while LGG and TLM supplementation
led to a 33 % (0.08 cm2) and 58 % (0.05 cm2) reduc-
tion respectively (Fig. 1d). TLM was effective in
restricting the HF diet induced atherosclerotic plaques
at the aortic sinus and the aortic tree to a level close
to that is seen in the ND group.
HF diet led to cholesterol crystals formation in plaque
and worsened various atherosclerosis related biomarker
levels which were improved by LGG and TLM to different
extents
Atherosclerosis is associated with worsened lipid and
adipokine profile, as well as various inflammation
related biomarkers. HF diet led to formation of chol-
esterol crystals in the atherosclerotic plaque that were
not observed in the other groups (Fig. 2a). HF diet
significantly elevated plasma levels of A-FABP, choles-
terol, MMP-9, sE-selectin, sICAM-1, sVCAM-1 and
endotoxin. Supplementing LGG in HF diet signifi-
cantly decreased such elevation except MMP-9; while
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TLM reduced the plasma levels of A-FABP, MMP-9,
sE-selectin, sVCAM-1 and endotoxin (Fig. 2, b, c, d,
e, f, g & h). On the other hand, while HF diet did
not induce any significant change in plasma level of
ghrelin nor IL-33, they were significantly increased by
TLM supplementation (Fig. 3h, i).
HF diet distorted colonial microbial profile and reduced
bacterial diversity, which were counteracted by TLM but
not LGG
In assessing statistically significant alterations in the bac-
terial community, only those taxa for which raw counts
reached at least 100 were considered. At the phylum
Fig. 1 Atherosclerotic plaque characterization. Lipid was stained red with Oil Red O at the aortic sinus (a, LHS), and Sudan IV in the aortic tree (b)
(Ascending aorta, arch of aorta, part of the descending aorta, brachiocephalic artery, left common carotid artery and left subclavian artery was
magnified at the RHS of a); the size of the lesion area at the aortic sinus (c) and the entire aortic tree (d) was quantified using ImageJ. Significant
difference of ND from the HF group was denoted by ###P < 0.001; significant difference of the treatment groups from HF group was donated by
***P < 0.001. ApoE−/− mice were fed on either normal chow diet (ND) or high fat (HF) diet with or without LGG (1×108CFU/day) or TLM (5 mg/kg/day)
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level, while no treatment group led to significant change
in the abundance of Firmicutes (Fig. 3a), HF diet in gen-
eral had led to significant decrease in Bacteroidetes
(Fig. 3b). The ratio Firmicutes/Bacteroidetes (F/B),
which usually increases during obese states and dysbiosis
[44, 45], was markedly elevated by HF diet. Supplement-
ing LGG and TLM in HF diet trended and significantly
lowered F/B respectively (Fig. 3c). At the genera level,
HF diet had led to significantly lower colonial abun-
dances of Eubacterium, Anaeroplasma, Oscillospira,
Roseburia and Dehalobacterium and higher abundances of
Allobaculum, Clostridum, Lactobacillus and Bifidobacteria
when compared to ND. The HF + LGG group had signifi-
cantly higher Lactobacillus and Clostridum abundances
compared to the ND and HF +TLM group; whereas the
HF +TLM group had significantly higher Helicobacter
abundance than HF alone (Fig. 3d).
The degree of OTUs shared between individual mice
and the four groups was summarized in the Venn dia-
gram (Fig. 3e). Greatest numbers of OTUs were shared
between mice in the same group. With respect to the
ND-HF comparison, 125 OTUs were common to both
groups while a large number of OTUs were still unique
to each group (370 for ND; 76 for HF). The HF + TLM
Fig. 2 Cholesterol crystals in atherosclerotic plaque and plasma concentrations of atherosclerosis related biomarkers. Atherosclerotic plaque
stained with Oil Red O at the aortic sinus, with blue arrows indicating the cholesterol crystals (a). Plasma concentration of A-FABP (b); cholesterol
(c); MMP-9 (d); sE-selectin (e); sVCAM-1 (f); sICAM-1 (g); endotoxin (h); ghrelin (i) and IL-33 (j). Significant difference of ND from the HF group was
denoted by #PP < 0.05, ##P < 0.01, ###P < 0.001; significant difference of the treatment groups from HF group was donated by *P < 0.05, **P < 0.01,
***P < 0.001. ApoE−/− mice were fed on either normal chow diet (ND) or high fat (HF) diet with or without LGG (1×108CFU/day) or TLM (5 mg/kg/day)
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group (174) had a greater overlap with the ND group
OTUs compared to the HF + LGG group (117), revealing
a more potent effect in maintaining normal bacterial
composition in the colon. The core microbiome com-
prised 79 OTUs that were present regardless of manipu-
lations to the diet.
Overall bacterial species diversity within the four
groups was examined using alpha diversity indexes
including observed number of species (Fig. 3f ) and the
chao1 index (Fig. 3g). The HF diet significantly reduced
the number of observed species (221 ± 27) compared to
the ND (381 ± 11). While the LGG supplementation did
not change the number of observed species (179 ± 4)
compared to HF diet alone, significant increase was seen
with TLM supplementation (265 ± 31). The number of
observed species in both the HF + LGG and HF + TLM
Fig. 3 Colonic gut microbiota alterations. Absolute abundances of (a) Firmicutes, (b) Bacteroidetes and the ratio of Firmicutes over Bacteroidetes
(c); relative abundances of 18 bacteria at genus level with raw counts of at least 100 (d); Venn diagram summarizing number of OTUs shared
between different groups (e); alpha diversity indexes including number of observed species (f) and Chao1 index (g); beta diversity indicated by
PCoA plot of unweighted UniFrac distance showing sample clustering by treatment groups (h). Significant difference of ND from the HF group
was denoted by #P < 0.05, ##P < 0.01; significant difference of the treatment groups from HF group was donated by *P < 0.05. ApoE−/− mice were
fed on either normal chow diet (ND) or high fat (HF) diet with or without LGG (1x108CFU/day) or TLM (5 mg/kg/day)
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groups remained significantly lower than the ND group
(Fig. 3f ). The impact of the HF diet was similarly indi-
cated (reduction in diversity) through the Chao1 index
(Fig. 3g). The significant higher number of observed spe-
cies and Chao1 index suggests that species richness in
the ND group was populated by the presence of many
more rare species. The unweighted UniFrac PCoA plot
revealed clear microbial diversity demarcation result-
ing from a HF diet compared to the ND group. Mice
of HF + LGG or HF + TLM groups aggregated into
distinct clusters as well based on their bacterial com-
munities (Fig. 3h).
Lowered bacterial diversity and alterations in several
colonic bacterial genera highly associated with changes
in several atherosclerosis parameters
As ND and HF had the most drastic differences detected
in atherosclerosis lesion size (Fig. 1), related biomarkers
(Fig. 2) and gut microbial abundances (Fig. 3), correla-
tions between the atherosclerotic parameters and bacter-
ial taxa were investigated between the groups (Fig. 4).
Only bacterial genera with an accumulative count of at
least 100 across all samples were studied. Of these, gen-
era that showed statistically significant abundance differ-
ence between ND and HF group were selected for the
correlation analysis. The HF diet induced significantly
lowered number of observed species and chao1 index; as
well as the colonic abundances of Eubacterium, Anaero-
plasma, Oscillospira, Dehalobacterium and Roseburia
(p < 0.05) showed significant negative correlations to
the increase in lesion size at the aortic sinus (p < 0.05).
Moreover, the reduction of the number of observed
species, chao1 index and abundances of Eubacterium,
Anaeroplasma and Oscillospira showed significant negative
correlations with lesion area of the entire aortic tree, plasma
A-FABP and cholesterol. Reduction in Eubacterium also
showed significant negative correlation with increase in
MMP-9 and sE-selectin; similar observations were also seen
between Dehaobacterium with A-FABP and Roseburia with
MMP-9. Notably decrease in Roseburia showed positive
correlations to the decrease in plasma IL-33. (Fig. 4). In
contrast, HF diet induced significant increase in abun-
dances of Lactobacillus, Allobaculum, Clostridium and
Bifidobacterium (p < 0.05), of which Clostridium and
Bifidobacterium showed significant positive correlations
with atherosclerotic lesion size at the sinus, aortic tree,
plasma A-FABP, cholesterol, MMP-9 or sE-selectin (Fig. 4).
Likewise, when correlations were analyzed between HF
& HF + LGG groups or HF & HF + TLM groups, signifi-
cant or strong tendency of similar correlations as noted
between ND & HF groups were observed, especially
between Eubacterium, Dehalobacterium, Roseburia and
Clostridium and lesion size, A-FABP and cholesterol
(Data not shown). Such correlations were not as strong
probably due to as compared to HF & ND, supplement-
ing LGG or TLM to HF induced a relatively smaller
changes in atherosclerotic parameters and changes in
bacterial genera abundances.
Discussion
From the earlier studies that showed bacterial abun-
dances in atherosclerotic plaques correlating with those
in the gastrointestinal tract [12]; patients with symptom-
atic atherosclerosis having an altered gut microbial
abundances and metagenome that was enriched in genes
encoding peptidoglycan synthesis but depleted in those
for phytoene dehydrogenase [19]; to recently identify-
ing gut microbiota dependent metabolites including
trimethylamine-N-oxide (TMAO) and Ɣbutyrovbe-
taine (ƔBB) from dietary phosphatidylcholine and
L-carnitine, that serve as strong predictors of coronary
artery disease [20, 46], have all suggested the gut micro-
biota as a very potential therapeutic target for reducing
atherosclerosis associated cardiovascular disease risks.
In this pilot study, we have first induced a strong ath-
erosclerotic phenotype with HF diet in ApoE−/− mice –
including significantly increase in atherosclerotic plaque
size and undesirable levels of atherogenic biomarkers;
then we compared the effects induced by microbial
(LGG) and pharmaceutical (TLM) intervention in terms
of gut microbial changes and different atherosclerosis
associated parameters. One limitation of the current
study is the relatively small sample size. As a pilot study,
a smaller animal numbers is typically used to generate
data as the foundation for future experiments. For
example, exciting insights have been generated from
some pilot studies with limited number of animals for
further studies [47, 48]. With our previous experience in
Fig. 4 Heat map describing the correlation of the alpha diversity
and abundances of different colonic bacterial genera and atherosclerosis
parameters. Bacteria genera shown were significantly altered (P< 0.05)
by HF diet feeding in ApoE−/− mice. The colors range from blue
(negative correlation; −1) to red (positive correlation; +1). Significant
correlations were noted by *P< 0.05, **P< 0.01 and ***P< 0.001; strong
tendency of correlation was noted by ^P< 0.10
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the lesion size expected in normal chow or high fat diet
in the ApoE−/− mice, the current number of mice used
were justified in generating meaningful statics [49]. In
essence, we have found the following from the pharma-
ceutical or probiotic intervention of gut microbiota in
relevance to the development of atherosclerosis:
Firstly, we found that both LGG and TLM could sig-
nificantly reduce HF diet induced atherosclerotic plaque
size, where TLM had a stronger plaque reducing power
(Fig. 1). While TLM is used as a control to reduce ath-
erosclerotic plaque size in ApoE−/− mice [35–37], certain
probiotics including L. acidophilus ATCC 4358 [18] and
Enterococcus faecium CRL183 & L. helveticus 416 [17]
had been previously shown to reduce atherosclerotic
plaque size in ApoE−/− mice and rabbits on hypercholes-
terolemic diet respectively. Such reduction might be
modulated through lowering oxidative stress and inflam-
mation [18].
Secondly, we showed that atherosclerotic improve-
ment led by LGG and TLM were indicative by several
associated biomarkers. LGG could reduce the HF diet
induced lipid related parameters including cholesterol
and A-FABP, an adipokine that is an important player in
lipid metabolism and a pathophysiological mediator of
atherosclerosis [50]. Cholesterol reduction has been im-
plied for lesser cardiovascular events owing to the result-
ant anti-inflammatory effects, improved plaque stability
and reduced risk of thrombotic complications [51].
While some probiotics had shown hypocholesterolemic
effects clinically [52, 53], the effects are likely to be
strain specific as others have failed to show the same
effect [54, 55]. Supplementation of LGG or TLM to HF
diet also resulted in reduction of cholesterol crystals in
the atherosclerotic plaque. As cholesterol crystals have
been suggested to be capable of physically perforating
cell membranes and the plaque cap, subsequently trig-
gering cell apoptosis and plaque rupture respectively
[56, 57], LGG and TLM could have further conferred
plaque stability. LGG also reduced soluble E-selectin,
ICAM-1 and VCAM-1, contributing to a less athero-
genic environment. Furthermore, LGG reduced endotox-
emia, a promising candidate that initiates obesity and
insulin resistance [3]. Indeed, probiotics had been sug-
gested in quite a few studies to be beneficial to cardio-
vascular system by improving lipid profiles [13, 16, 58]
and endotoxemia [58]. One potential mechanism to how
LGG improved lipid profile was its ability to produce
exopolysaccharides [59]. Exopolysaccharides can serve as
a protective shield for LGG to fight against the host in-
nate immunity [60] and at the same time modify the en-
teric gut microbiota and reduce liver and serum
cholesterol and triglyceride concentrations [59]. Certain
L. rhamnosus strains can also produce specific delipidat-
ing molecules, such as conjugated linoleic acid [61, 62]
that interfere with host metabolism by modulating
energy expenditure, fatty acid oxidation, lipolysis and
lipogenesis [61]. While LGG induced a relatively less
alteration in the gut microbial abundances in this study,
it should be noted that the lipid modulating effects
exerted by Lactobacillus can be independent to its intes-
tinal colonization [63].
TLM resulted in similar significant or trended reduc-
tion in the tested plasma biomarkers, especially in
MMP-9 and endotoxin. The inhibitory effects of TLM
on A-FABP [64, 65] and monocytic cell adhesions [66]
may have been mediated by PPARƔ activation; and on
MMP-9 [67–72] by Elk-1 phosphorylation inhibition
[67]. While TLM was previously shown to lower choles-
terol [73, 74], possibly through inhibiting intestinal chol-
esterol absorption [74], such reduction was not seen in
the current study. Interestingly, TLM was able to in-
crease plasma ghrelin and IL-33 concentrations, suggest-
ing TLM may contribute to an anti-atherogenic
environment by mediating Th1 to Th2 responses [75, 76].
Thirdly, we demonstrated that HF diet induced athero-
sclerosis was associated with a much lower colonic mi-
crobial diversity. The reduced microbial diversity may be
from the selected growth of bacteria that better utilized
fatty acids as their energy source, leading to their domi-
nances and out-competing the growth of others. Resist-
ance to pathogenic bacteria colonization may be reduced
resulting in worsened gut barrier functions. Although
LGG did not increase gut microbial diversity and a less
distinct clustering in the PCoA plot that was further
away from ND in this study, L. plantarum had been
shown to increase bacterial diversity in the colon in men
with incipient atherosclerosis [77]. The restoration of
bacterial diversity by TLM suggests that supplementing
TLM was able to blunt the drop in the microbial assem-
blage, its potential ability to sustain a more diverse bac-
terial community despite the same HF content.
Furthermore, we have identified five bacteria genera
that are most likely protective against atherosclerosis –
Eubacerium, Anaeroplasma, Oscillospira, Roseburia and
Dehalobacterium. These microbes correlated strongly
with atherosclerotic lesion area at the aortic sinus and
aortic tree, plasma cholesterol, A-FABP and MMP-9.
Recently, Eubacterium and Roseburia were found to be
enriched in the gut microbiota in healthy controls
against those with symptomatic atherosclerosis [19].
Eubacteria and Roseburia, in our pilot study, were at
much higher abundance in the ND and HF + LGG
groups compared to the HF group. As Eubacteria and
Roseburia are butyrate producing bacteria [78, 79], they
may inhibit proliferation of vascular smooth muscle cells
[80] conferring athero-protective effects. Oscillospira is
often found strongly increased in hosts fed on fresh
green fields [81], and Anaeroplasma is correlated with
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better crude fiber digestibility [82]. Higher abundances
of Oscillospira and Anaeroplasma may have conferred
protective effects based on their capacity on fiber metab-
olism. For example, O. guillermondii, together with a
more abundant network of primary fiber degraders were
found associated with lower BMI [83].
On the other hand, HF diet had significantly enhanced
the colonic population of Lactobacillus, Allobaculum,
Bifidobacterium and Clostridium, among which the
increase in Bifidobacterium and Clostridium were posi-
tively correlated to atherosclerotic plaque size, A-FABP
and cholesterol. The main elevated Bifidobacteria species
in the HF group was B. pseudologum, which is the most
predominant Bifidobacterium species in the infant gut
[84] but insufficiently understood. Interestingly, Bifido-
bacterium were also found to have a significant positive
correlation with TMAO, the gut microbiota dependent
metabolite that predicts CVD risks [85]. With the
complete genome of B. pseudologum completed [86], the
functional capacity of the Bifidobacterium genera should
be further explored for its relationship with atheroscler-
osis. Clostridium cocleatum, which was significantly
elevated in the HF group, can degrade mucin [87] thus
could impair the gut barrier and thereby augment sys-
temic inflammation. As for Allobaculum, which corre-
lated positively with atherosclerotic plaque size and
MMP-9 in our pilot study, and TMAO in others [85],
was also associated with low fat [88] and prebiotics [89]
feeding. Lactobacillus, while being elevated in the HF
diet, did not have any significant correlation with the
atherogenic parameters tested in this study. So far, cer-
tain Lactobacillus species had been associated with obes-
ity and weight gains while others with weight loss, for
example, L. reuteri enrichment and L. casei/paracasei
and L. plantanum depletion in an obese gut metagen-
ome [90]. The complete genomes of seven different
weight gain or weight protection associated Lactobacil-
lus were recently sequenced and genes involved in car-
bohydrates and lipid metabolism and bacteriocin were
identified to have a prominent role in nutrients harvest-
ing and defense against oxidative stress [91], thus con-
tributing to their associations to pro/anti-obesity.
Conclusion
In this pilot study, we showed that microbial interven-
tion with LGG or pharmaceutical intervention with
Telmisartan were effective in reducing atherosclerotic
plaque size and improveing plasma levels of various ath-
erosclerosis associated biomarkers to different extents.
TLM was more effective than LGG in altering the gut
microbiota – in terms of colonic bacterial diversity and
abundances closer to that observed when fed a ND diet.
A lowered colonic bacterial diversity, abundances of
Eubacterium, Anaeroplasma, Roseburia, Oscillospira,
Dehalobacterium and increased Clostridium and Bifido-
bacteria was associated with an adverse atherogenic pro-
file, especially atherosclerotic plaque size, plasma levels
of A-FABP and cholesterol. As A-FABP, a suggested
nexus where nutritional and inflammatory pathways
meet [92], and cholesterol are crucial players in lipid
metabolism, future studies focusing on the functional
capacities in lipid metabolism of the above-mentioned
bacteria will be valuable in understanding their impact
on atherogenic development and to understand whether
they are an active conspirator to pathology or a silent
reflection of disease progression/outcome.
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